Rainmaker Worldwide Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities (a) Market Information Our common stock is quoted on the OTC: Pink under the symbol “RAKR”. The high and low bid prices of our common stock for the periods indicated below are as follows: Quarter Ended High* Low* December 31, 2024 $ 0.0091 $ 0.0090 September 30, 2024 $ 0.04 $ 0.02 June 30, 2024 $ 0.035 $ 0.0313 March 31, 2024 $ 0.0425 $ 0.0413 December 31, 2023 $ 0.0675 $ 0.05 September 30, 2023 $ 0.0225 $ 0.0175 June 30, 2023 $ 0.045 $ 0.035 March 31, 2023 $ 0.04 $ 0.0325 *Source: yahoo!finance Historical Data Quotations reflect interdealer prices, without retail mark up, markdown or commissions and may not represent actual transactions. (b) Holders The number of holders of record of RAKR common stock at the time of filing was approximately 4,153. Many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, so we are unable to estimate the number of stockholders represented by the record holders. The transfer agent for RAKR common stock is Pacific Stock Transfer, 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119. (c) Dividends The Company has not paid any cash dividends to date and does not anticipate or contemplate paying dividends in the foreseeable future. It is the present intention of management to utilize all available funds for the development of the business. (d) Securities Authorized for Issuance Under Equity Compensation Plans On January 21, 2020, the Company entered into a three-year consulting agreement with a company controlled by its new CEO. The contract included 144,000 warrants with an exercise price of $5.00 vesting in equal amounts commencing the effective date of the contract. On December 31, 2020, this contract was terminated. The warrants vested immediately, and the exercise price was amended to $2.50. As well, the Company granted an additional 20,000 warrants which vested immediately at an exercise price is $2.50. All expire December 31, 2025. As of January 8, 2024, these warrants have been repriced at $0.0347. 12 On October 1, 2020, the Company entered into a consulting agreement with an Advisor which granted warrants in full compensation for services. It included 540,000 warrants at an exercise price of $7.50 now expired as of October 1, 2023. A further 600,000 warrants were issued at an exercise price of $3.75 expiring October 1, 2025. On April 1, 2021, the Company granted 164,000 options as part of an amendment to an Executive Consultant’s contract; 5,000 options vest per month commencing April 1, 2021 with a term of 5 years and exercisable at a price of $2.50 per Share. As of January 8, 2024, these options have been repriced at $0.0347. On December 21, 2021, the Company granted 20,000 options to each of the two new Directors; for each, 4,000 options vested immediately and the balance vests over the remaining term of their appointment; each with a term of 5 years and exercisable at $2.50 per share or with a 20% discount to market based on a 30-day VWAP if it falls below $2.50, not to go below $1.75. These options are fully vested as of December 31, 2023. As of January 8, 2024, these options have been repriced at $0.0347. On July 1, 2022, the Company granted 60,000 options as compensation to the newly filled position, VP Sales and 100,000 to the VP Finance. 25,600 and 20,000 options respectively vested immediately and the remaining options vest over one year, with a term of 5 years and exercisable at $3.00 per share. In January, 2024, the Board of Directors modified the exercise price to $0.0347 per share. January 8, 2024, the Board of Directors granted 264,000 fully vested options to the Company’s CEO, with a term of 5 years and exercisable at $0.0347 per share (70% of the 30-day Volume Weighted Average Price prior to this date). These options are the first options granted to the CEO who forewent this compensation in the past to benefit the Company. The CEO is now aligned with the executive management compensation. At the same time, the Board of Directors modified 528,000 fully vested shares allocated to executives, directors and former management to reflect the same exercisable price of $0.0347 per share. Item 6. Selected Financial Data Not applicable.